ストックスクリーナーアプリを入手
13.82
0.14%
0.02
前日終値:
$13.80
開ける：
$13.76
24時間の取引高:
974.22K
Relative Volume:
0.58
時価総額：
$1.72B
収益：
$181.74M
当期純損益:
$-599.49M
株価収益率:
-2.7585
EPS:
-5.01
ネットキャッシュフロー:
$-604.32M
1週間 パフォーマンス:
-6.62%
1か月 パフォーマンス:
-27.03%
6か月 パフォーマンス:
-29.74%
1年 パフォーマンス:
-51.68%
1日の値動き範囲:
$13.66
$13.99
1週間の範囲:
$13.66
$15.65
52週間の値動き範囲:
$13.66
$30.41
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
名前
Arrowhead Pharmaceuticals Inc
セクター
電話
626-696-4702
住所
177 E COLORADO BLVD, PASADENA, CA
ARWR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
13.82 | 1.72B | 181.74M | -599.49M | -604.32M | -5.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-05 | 開始されました | Goldman | Neutral |
| 2023-12-04 | 開始されました | BofA Securities | Buy |
| 2023-09-19 | 開始されました | Citigroup | Neutral |
| 2023-07-21 | 開始されました | TD Cowen | Outperform |
| 2023-05-12 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-12 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-11 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 再開されました | Goldman | Buy |
| 2021-08-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-11-19 | 開始されました | Citigroup | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-05-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-04-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 開始されました | Goldman | Neutral |
| 2020-01-21 | 開始されました | SVB Leerink | Underperform |
| 2019-12-13 | 開始されました | Oppenheimer | Perform |
| 2019-11-29 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-27 | 繰り返されました | B. Riley FBR | Buy |
| 2019-11-25 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-10-03 | 開始されました | Robert W. Baird | Outperform |
| 2018-09-07 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-08-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Arrowhead Pharmaceuticals Inc (ARWR) 最新ニュース
Arrowhead stock hits 52-week low at $14.21 amid market challenges - Investing.com Canada
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company - Yahoo Finance
Arrowhead Pharmaceuticals Is Finally Arriving (NASDAQ:ARWR) - Seeking Alpha
(ARWR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
RNA Therapies Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight - The Globe and Mail
First Capital REIT Announces March 2025 Distribution - The Globe and Mail
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by US Bancorp DE - Defense World
Bank of New York Mellon Corp Sells 36,341 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead stock holds Buy rating, $80 target from H.C. Wainwright By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL
Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 4.2% drop adds to a year losses - Simply Wall St
Buy Rating for Arrowhead Pharmaceuticals Driven by Promising ARO-C3 Trial Results and Strategic Pipeline Advancements - TipRanks
Arrowhead Pharmaceuticals Stock Dips Despite Promising Study - TipRanks
Mutual of America Capital Management LLC Sells 1,519 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy - BioSpace
Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients - Marketscreener.com
Arrowhead Pharma Reports Positive Topline Data From Phase 1/2 Study Of ARO-C3 - Nasdaq
Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy - Marketscreener.com
Arrowhead Clinical Trial: 87% C3 Reduction in IgA Nephropathy Patients - StockTitan
Arrowhead Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Arrowhead Pharmaceuticals CEO sells $5.27 million in stock By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases - Lelezard
Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment - Marketscreener.com
Arrowhead advances RNAi obesity treatments in clinical trials - Investing.com
Arrowhead advances RNAi obesity treatments in clinical trials By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals CEO sells $5.27 million in stock - Investing.com
Familial Chylomicronemia Syndrome Market to Expand - openPR
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Position Trimmed by Principal Financial Group Inc. - Defense World
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Galveston County Daily News
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) – Company AnnouncementFT.com - Financial Times
Rhumbline Advisers Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Objective long/short (ARWR) Report - Stock Traders Daily
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity - The Bakersfield Californian
Van ECK Associates Corp Raises Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Empowered Funds LLC Takes $268,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions (NASDAQ:ARWR) - Seeking Alpha
Fat, not muscle: drugmakers in race for next weight-loss breakthrough - Reuters
Zacks Small Cap Has Pessimistic Outlook of ARWR Q2 Earnings - MarketBeat
Analysts Offer Predictions for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough - Investing.com
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
B. Riley Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Guidewire Software set to join S&P MidCap 400; Arrowhead Pharmaceuticals to join S&P SmallCap 600 - MSN
Leerink Partnrs Analysts Raise Earnings Estimates for ARWR - MarketBeat
Arrowhead Pharmaceuticals Inc (ARWR) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):